Professional Documents
Culture Documents
Decisions
Session Three
The Capital Investment Process
• Capital Budget
• List of investment projects under consideration by a firm
• Do not add fudge factors to cost of capital
• Postaudit
• Review of project to see if met forecasts
Types of Analysis
• Sensitivity
• Analyzes effects of changes in sales, costs, etc., on project
• Scenario
• Project analysis given particular combination of assumptions
• Break Even
• Level of sales (or other variable) at which project breaks even
• Real Options
• Choice is valuable, the value of an option
• Decision Trees
• Sequential decisions and possible outcomes
Establish the Base Case
6
Annuity Equation for NPV calculations
8
Sensitivity Analysis: Optimistic
NPV calculations—
Optimistic scenario of
market size:
Sales = 1.1*37.5 = 41.25
Variable costs = 1.1*30 = 33
c
Sensitivity Analysis: Pessimistic
NPV calculations—
Pessimistic scenario of
market size: ?
?
Sales = 0.9*37.5 = ?
Variable costs = 0.9*30 = ?
?
Sensitivity Analysis
11
Sensitivity Analysis
14
Scenario Analysis
15
Scenario Analysis
Revise estimated sales and costs for high oil prices and recession
Base Case High Oil Prices and Recession
Unit sales 100,000 100,000*1.04 = 104,000
Unit price 375,000 375,000*1.15 = 431,250
Sales revenue 37.5 billion 104,000*431.250 = 44.85 billion
Unit variable cost 300,000 300,000*1.15 = 345,000
Variable cost 30 billion 104,000*345,000 = 35.88 billion
Fixed cost 3 billion 3 * 1.15 = 3.45 billion
16
Scenario Analysis
Breakeven Analysis
200 PV Outflows
19.6
85 200 Sales,
thousands
Breakeven Analysis
60 Revenues
Sales, thousands
60 200
Real Options
• Option to expand
• Option to abandon
• Timing option
• Flexible production facilities
Option to Abandon
23
Option to Abandon
Buoyant
$24 million
Technology A
Sluggish
$16 million Continue
$22.5 million
Buoyant
Abandon
$18.5 million
Continue $15 million
Technology B
Sluggish
Abandon
$18.5 million
24
Option to Abandon
25
Decision Trees
27
Decision Tree: Example
28
Decision Tree: Example
Invest $130? FDA approval for widely use
Phase 2 (2 years) Phase 3 (3 years)
PV = 700
FDA disapproves
PV = 0
29
Decision Tree
Probabilities
• Phase two
• Trail successful : 44%
• Trail fail : 56%
• Phase three
• FDA approval : 80%
• Wide use (over the counter) : 25%
• Limited use (prescription) : 50%
• Restricted use (with medical supervision) : 25%
• FDA reject : 20%
30
Decision tree
$700 (.80)
- $130
.25
$0 (.20)
$ 300 (.80)
- $18 .44 .50 - $130
Invest .56
Yes / No $0 $ 0 (.20)
.25
$ 100 (.80)
NPV= ? - $130
$ 0 (.20)
Decision tree
$700 (.80)
- $130
560
.25
$ 0 (.20)
$ 300 (.80)
- $18 .44 .50 - $130
240
Invest .56
Yes / No $0 $ 0 (.20)
.25
$ 100 (.80)
NPV= ? - $130
80
$ 0 (.20)
Decision tree
$700 (.80)
- $130
560
.25
$ 0 (.20)
$ 300 (.80)
- $18 .44 .50 - $130
240
Invest .56
Yes / No $0 $ 0 (.20)
.25
$ 100 (.80)
NPV= ? - $130
80
$ 0 (.20)
Decision tree
$700 (.80)
NPV = $295
- $130
560
.25
$ 0 (.20)
$ 300 (.80)
- $18 .44 .50 - $130
240
Invest .56
Yes / No $0 $ 0 (.20)
.25
$ 100 (.80)
NPV= ? - $130
80
$ 0 (.20)
Decision tree
$700 (.80)
NPV = $295
- $130
560
.25
$ 0 (.20)
$ 300 (.80)
- $18 .44 .50 - $130
240
Invest .56 NPV = $52
Yes / No $0 $ 0 (.20)
.25
$ 100 (.80)
NPV= ? - $130
NPV = - $69 80
(do not invest, so NPV = 0)
$ 0 (.20)
Decision tree
$700 (.80)
NPV = $295
- $130
560
.25
$ 0 (.20)
NPV = $83 $ 300 (.80)
- $18 .44 .50 - $130
240
NPV = $52
Invest .56
Yes / No $0 $ 0 (.20)
.25
$ 100 (.80)
NPV= ? - $130
80
NPV = - $69
(do not invest, so NPV = 0)
$ 0 (.20)
Decision tree
$700 (.80)
NPV = $295
- $130
560
.25
$ 0 (.20)
NPV = $83 $ 300 (.80)
- $18 .44 .50 - $130
240
NPV = $52
Invest .56
Yes / No $0 $ 0 (.20)
.25
$ 100 (.80)
NPV= $19 - $130
80
NPV = - $69
(do not invest, so NPV = 0)
$ 0 (.20)
Decision tree
$700 (.80)
NPV = $295
- $130
560
.25
$ 0 (.20)
NPV = $83 $ 300 (.80)
- $18 .44 .50 - $130
240
NPV = $52
Invest .56
Yes / No $0 $ 0 (.20)
.25
$ 100 (.80)
NPV= $19 - $130
80
NPV = - $69
(do not invest, so NPV = 0)
$ 0 (.20)